REPLIGEN CORPRGENEarnings & Financial Report

Nasdaq · pharmaceutical industry

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

Revenue

$188.8M

Gross Profit

$100.5M

Operating Profit

$16.8M

Net Profit

$14.9M

Gross Margin

53.2%

Operating Margin

8.9%

Net Margin

7.9%

YoY Growth

21.9%

EPS

$0.26

Financial Flow

REPLIGEN CORP Q3 2025 Financial Summary

REPLIGEN CORP reported revenue of $188.8M for Q3 2025, with a net profit of $14.9M (7.9% margin). Cost of goods sold was $88.3M, operating expenses totaled $83.7M.

Key Financial Metrics

Total Revenue	$188.8M
Net Profit	$14.9M
Gross Margin	53.2%
Operating Margin	8.9%
Report Period	Q3 2025

REPLIGEN CORP Annual Revenue by Year

REPLIGEN CORP annual revenue history includes year-by-year totals (for example, 2024 revenue was $634.4M).

Year	Annual Revenue
2024	$634.4M
2023	$638.8M
2022	$801.5M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$155.7M	$151.3M	$154.1M	$154.9M	$174.1M	$169.2M	$182.4M	$188.8M
YoY Growth	-16.6%	-17.1%	-3.2%	9.7%	11.8%	11.8%	18.4%	21.9%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$2.82B	$2.85B	$2.86B	$2.83B	$2.83B	$2.85B	$2.90B	$2.92B
Liabilities	$853.2M	$878.7M	$875.6M	$814.0M	$856.9M	$866.7M	$839.9M	$840.6M
Equity	$1.97B	$1.97B	$1.99B	$2.02B	$1.97B	$1.99B	$2.06B	$2.08B